Skip to main content
  • Poster presentation
  • Open access
  • Published:

Metabolic evaluation of Study M05-730: LPV/r tablets QD vs. BID, co-administered with tenofovir DF + emtricitabine in ARV-naïve HIV-1 infected subjects


Evaluation of changes in lipid ratios and tools such as the Framingham risk equation may provide a more comprehensive measure of the implications of lipid changes.


664 ARV-naive HIV-1-infected subjects were randomized 1:1:1:1 to lopinavir/ritonavir (LPV/r) once-daily (QD) SGC, twice-daily (BID) SGC, QD tablet, BID tablet for eight weeks. All subjects received tenofovir (TDF) + emtricitabine (FTC) QD. At week 8, subjects taking LPV/r SGC were switched to the tablet formulation while maintaining their QD or BID dosing schedule. All subjects will be followed for up to 96 weeks. Metabolic evaluations at baseline (BL) and week 48 are presented.

Summary of results

BL characteristics were similar between QD and BID groups. Through 48 weeks, 15% (QD) and 17% (BID) discontinued prematurely for various reasons. Only two patients discontinued due to either elevated triglyceride (TG) or total cholesterol (TC) levels. Statistically significant mean increases were observed in individual lipid parameters through 48 weeks (Table 1). However, among all subjects combined, decreases through 48 weeks were observed for both TC:HDL ratio (from 4.40 to 4.21, p = 0.102) and LDL:HDL ratio (from 2.69 to 2.34, p < 0.001). 80% of subjects overall who had TG values < 2.825 mmol/L at BL maintained these levels at week 48. Of subjects who had TC in the desirable NCEP range (< 5.2 mmol/L) at BL, 72% maintained these levels at week 48. 87% of subjects who had LDL in the optimal/near optimal NCEP range (< 3.38 mmol/L) at BL also had levels in this range at week 48. The proportion of subjects with low HDL (<1.04 mmol/L) by NCEP decreased from 60% to 33% from BL to week 48. The mean 10-year CV risk, including the effect of the change in age over 48 weeks, remained unchanged over 48 weeks when the LDL criteria were used (4.63% to 4.60%, p = 0.750), but increased slightly when the TC criteria were used (4.25% to 5.02%, p < 0.001). HOMA did not significantly change from baseline to week 48 (mean change +0.06).

Table 1 Mean basline (BL), week 48, and changes from BL in lipid parameters.


Measures of lipid ratios and Framingham models are better assessments of cardiovascular risk than individual lipid parameters. Through 48 weeks, in subjects treated with a LPV/r-based regimen, these measures (TC:HDL and LDL-C:HDL ratios) and Framingham (TC-based and LDL-based) 10-year cardiovascular risk were minimally impacted.

Author information

Authors and Affiliations


Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Da Silva, B., Cohen, D., Marsh, T. et al. Metabolic evaluation of Study M05-730: LPV/r tablets QD vs. BID, co-administered with tenofovir DF + emtricitabine in ARV-naïve HIV-1 infected subjects. JIAS 11 (Suppl 1), P110 (2008).

Download citation

  • Published:

  • DOI: